Therapeutic level in long term anticoagulant therapy after myocardial infarction

Bjerkelund, C

doi:10.1016/0002-9149(63)90056-0

Cited by 26 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are 10 published randomized trials of long-term oral anticoagulant therapy in patients with acute myocardial infarction 42,[82][83][84][85][86][87][88][89][90][91][92] (Table 3). In seven of these trials, [82][83][84][87][88][89][90][91][92] anticoagulant therapy was compared with placebo or control treatment; in the eighth, 85 anticoagulant therapy was compared with aspirin; in the ninth, 86 anticoagulant therapy was compared with aspirin or placebo; and in the 10th, 42 fixed low doses of warfarin (1 mg or 3 mg) combined with aspirin were compared with aspirin alone. The frequency of major bleeding ranged from 0 to 10% and fatal bleeding ranged from 0 to 2.9%.…”

Section: Ischemic Heart Diseasementioning

confidence: 99%

Hemorrhagic Complications of Anticoagulant Treatment

Levine¹,

Raskob²,

Landefeld³

et al. 1998

Chest

257

240

View full text Add to dashboard Cite

ACCP ϭ American College of Chest Physicians; APTT ϭ activated partial thromboplastin time; ASA ϭ acetylsalicylic acid; ASPECT ϭ Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis; INR ϭ international normalized ratio; LMW ϭ low molecular weight; PT ϭ prothrombin time; SPAF ϭ Stroke Prevention in Atrial Fibrillation (CHEST 2001; 119:108S-121S) T he major complication of anticoagulant therapy is bleeding. In this review, the incidence of hemorrhage in patients receiving oral anticoagulants or heparin and the clinical and laboratory risk factors that predispose to bleeding are discussed. The focus is on major bleeding and fatal bleeding. Details of the method used to select relevant articles can be found in the five previous symposia of the American College of Chest Physicians (ACCP). 1-5 Bleeding was classified as major if it was intracranial or retroperitoneal, if it led directly to death, or if it resulted in hospitalization or transfusion. 1,2 Although bleeding is the major side effect of anticoagulant therapy, it should not be considered in isolation of potential benefit, ie, reduction in thromboembolism.

show abstract

Section: Ischemic Heart Diseasementioning

confidence: 99%

Hemorrhagic Complications of Anticoagulant Treatment

Levine¹,

Raskob²,

Landefeld³

et al. 1998

Chest

257

240

View full text Add to dashboard Cite

show abstract

“…Or is the rate of reinfarction more valid ? Bjerkelund (1963) states that recurrences should be used to assess therapy, as there is poor correlation b_etween sudden death and autopsy demonstration of recent occlusion. When this criterion is.…”

Section: Discussionmentioning

confidence: 99%

“Thrombotest” and Prothrombin Time: A Controlled Clinical Trial

Kronenberg

Firkin

1965

Australasian Annals of Medicine

View full text Add to dashboard Cite

show abstract

“…In two studies 44,45,68 underlying risk factors for bleeding were described. In the Sixty-Plus trial 68 four patients with malignancies bled.…”

Section: Atrial Fibrillationmentioning

confidence: 99%

“…In the Sixty-Plus trial 68 four patients with malignancies bled. In the study by Bjerkelund 44,45 two patients bled from malignant lesions. In Bjerkelund's study, four out of five cerebral bleeding episodes occurred in hypertensive patients, three patients bled from duodenal ulcer, two had hematuria due to underlying urolithiasis, and one bled from an occult gastric carcinoma.…”

Section: Atrial Fibrillationmentioning

confidence: 99%